Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib + lapatinib versus lapatinib alone in HER2-positive inflammatory breast cancer
2006-006537-40Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in inflammatory breast cancer (IBC) and breast cancer comparing Pazopanib + lapatinib with Lapatinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2007; status: completed.
02
Drugs
pazopaniblapatinib
03
Conditions
inflammatory breast cancer (IBC)breast cancer
Beyond the preview
Go deeper on 2006-006537-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006537-40.